Selection of optimum process conditions in combinatorial microreactors is essential if the combinatorial synthesis process is to be correlated with the synthesis process on a more conventional scale and the materials are to have the desired chemical properties. We have developed a new methodology for the high-throughput multiparameter optimization of polymerization reaction conditions in arrays of microreactors. Our strategy is based on the application of nondestructive spectroscopic techniques to measure chemical properties of polymers directly in individual microreactors followed by the multivariate spectral descriptor analysis for rapid determination of the optimal process conditions. We have demonstrated our strategy in the high-throughput multiparameter optimization of process conditions in thin-film melt polymerization reactions performed in 96-microreactor arrays for combinatorial screening of new polymerization catalysts. The combinatorial polymerization system was optimized for the best processing parameters using a set of input variables that included reactant parameters (relative amounts of starting components and catalyst loading) and processing variables (reaction time, reaction temperature, and inert gas flow rate). The measured output parameters were the chemical properties of materials and reproducibility of the material formation in replicate polymerizations in microreactors. Spatially resolved nondestructive evaluation of polymer formation was performed directly in individual microreactors and provided information about the spatial homogeneity of polymers in microreactors. It showed to be another powerful indicator of the reproducible polymerization process on the combinatorial scale. Although the methodology described here was implemented for high-throughput optimization of polymerization conditions, it is more general and can be further implemented for a variety of applications in which optimization of process parameters can be studied in situ or off-line using spectroscopic and other tools.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/cc020062g | DOI Listing |
SLAS Technol
December 2024
Sanofi Integrated Drug Discovery, 350 Water St, Cambridge, MA, USA.
Pharmaceutical and biotechnology companies are increasingly being challenged to shorten the cycle time between design, make, test, and analyze (DMTA) compounds. Automation of multiplex assays to obtain multiparameter data on the same robotic run is instrumental in reducing cycle time. Consequently, an increasing need in automated systems to streamline laboratory workflows with the goal to expedite assay cycle time and enhance productivity has grown in industrial and academic institutions in the past decades.
View Article and Find Full Text PDFJ Allergy Clin Immunol
November 2024
Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, United Kingdom; Cellular Genetics, the Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom. Electronic address:
Immune responses require complex, spatially coordinated interactions between immune cells and their tissue environment. For decades, we have imaged tissue sections to visualize a limited number of immune-related macromolecules in situ, functioning as surrogates for cell types or processes of interest. However, this inevitably provides a limited snapshot of the tissue's immune landscape.
View Article and Find Full Text PDFCommun Biol
November 2024
Quiver Bioscience, Cambridge, MA, USA.
Fragile X syndrome (FXS) is a neurodevelopmental disorder caused by hypermethylation of expanded CGG repeats (>200) in the FMR1 gene leading to gene silencing and loss of Fragile X Messenger Ribonucleoprotein (FMRP) expression. FMRP plays important roles in neuronal function, and loss of FMRP in mouse and human FXS cell models leads to aberrant synaptic signaling and hyperexcitability. Multiple drug candidates have advanced into clinical trials for FXS, but no efficacious treatment has been identified to date, possibly as a consequence of poor translation from pre-clinical animal models to human.
View Article and Find Full Text PDFPLoS One
October 2024
Mikro Biyosistemler A.S., Ankara, Turkiye.
Lab Chip
October 2024
IBG-1: Institute of Bio- and Geosciences, Forschungszentrum Jülich GmbH, Jülich, Germany.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!